Global MarketsIMPORTANT
Roche (ROP SW) 9M 2026 (CHF): Sales 46.5bln (prev. 45.86bln Y/Y); Q3 Sales 16.13bln (exp. 15.79bln). Reaffirms FY26 outlook for mid-single-digit sales growth and high-single-digit core EPS growth at constant FX
StockNow breaking-news AI analysis
Roche reported 9M and Q3 2026 sales, segment growth rates and stated demand drivers, and reaffirmed FY26 sales and core EPS growth outlook.
News detail
Pharmaceuticals sales +2%, +7% CER. Diagnostics sales flat, +4% CER. Commentary: Growth driven by strong demand for Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo, while Diagnostics growth was supported by core lab and pathology demand, partly offset by healthcare pricing reforms in China.
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.